Related Experiment Video
Updated: Jul 16, 2025

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Duration of antifungal treatment in mold infection: when is enough?
Vera Portillo1, Dionysios Neofytos
1Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
Purpose Of Review:
Although invasive mold infections (IMI) are a major complication in high-risk populations, treatment duration has not yet been well defined.
Recent Findings:
Guidelines suggest documenting clinical/radiological resolution and immunological recovery before stopping antifungal treatment, after a minimum duration of treatment of 3 months for invasive pulmonary aspergillosis, while longer (up to 6 months) duration is proposed for the treatment of invasive mucormycosis. However, data on and definitions of clinical/radiological resolution and immune recovery remain scarce. Limited real-life data suggest that often much longer courses of treatment are given, generally in the context of continuous immunosuppression, occasionally defined as secondary prophylaxis. However, clearcut definition and distinction of secondary prophylaxis from antifungal treatment remain to be defined.
Summary:
Decisions to stop antifungal treatment are based on poorly defined treatment responses and immune reconstitution and experts' opinions. More evidence is needed to determine the optimal duration of treatment of IMI. Well designed, easy to use, and realistic algorithms to help clinicians decide when to stop antifungal treatment are urgently needed.
Insights
Defining the optimal duration for antifungal treatment of invasive mold infections (IMI) is challenging due to poorly understood resolution criteria. Evidence is needed to guide decisions on stopping treatment in immunocompromised patients.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Medicine
Background:
- Invasive mold infections (IMI) are serious complications in immunocompromised individuals.
- Current guidelines lack precise definitions for treatment cessation, relying on clinical/radiological resolution and immune recovery.
- Existing data suggest prolonged treatment durations, often blurring the line with secondary prophylaxis.
Approach:
- Review of current guidelines and available real-life data on IMI treatment duration.
- Analysis of the challenges in defining treatment response and immune reconstitution.
- Identification of the need for evidence-based algorithms for treatment de-escalation.
Key Points:
- Optimal duration for antifungal therapy in IMI remains undefined.
- Definitions for clinical/radiological resolution and immune recovery are scarce.
- Distinguishing prolonged treatment from secondary prophylaxis requires clear definitions.
Conclusions:
- Decisions to stop antifungal treatment for IMI are based on limited evidence and expert opinion.
- More research is essential to establish optimal treatment durations.
- Development of practical algorithms is crucial for guiding clinicians in IMI management.
More Related Videos
07:19A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
Published on: October 21, 2010
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Antimicrobial Effectiveness
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...